Rani Therapeutics Ownership 2024 | Who Owns Rani Therapeutics Now?
Institutional Ownership
12.21%
Insider Ownership
48.88%
Retail Ownership
38.91%
Institutional Holders
37.00
Rani Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | 2.69% | - | 685,303 | 16,956 | 2.54% | 2,131,292 | Mar 31, 2024 |
| NAN FUNG GROUP HOLDINGS LTD | 1.94% | 1.42% | 493,584 | - | - | 1,535,046 | Mar 31, 2024 |
| UNITED SERVICES AUTOMOBILE ASSOCIATION | 1.89% | 0.04% | 481,300 | - | - | 1,496,843 | Mar 31, 2024 |
| ALPHABET INC. | 1.76% | 0.06% | 448,492 | - | - | 1,394,810 | Mar 31, 2024 |
| STIFEL FINANCIAL CORP | 0.52% | 0.00% | 132,434 | 82,168 | 163.47% | 411,866 | Mar 31, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.51% | - | 130,906 | 17,277 | 15.20% | 407,223 | Mar 31, 2024 |
| BANK OF AMERICA CORP /DE/ | 0.49% | - | 124,505 | 10,246 | 8.97% | 387,211,000 | Mar 31, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.28% | 0.00% | 70,300 | 26,600 | 60.87% | 219,000 | Mar 31, 2024 |
| BLACKROCK INC. | 0.25% | - | 63,583 | - | - | 197,743 | Mar 31, 2024 |
| LASRY MARC | 0.25% | 0.17% | 62,887 | - | - | 195,579 | Mar 31, 2024 |
| KING LUTHER CAPITAL MANAGEMENT CORP | 0.22% | 0.00% | 56,129 | - | - | 174,561 | Mar 31, 2024 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.20% | 0.00% | 51,500 | - | - | 160,165 | Mar 31, 2024 |
| MOTCO | 0.19% | 0.01% | 48,129 | - | - | 149,681 | Mar 31, 2024 |
| BROWN ADVISORY INC | 0.13% | 0.00% | 33,911 | - | - | 105,463 | Mar 31, 2024 |
| STATE STREET CORP | 0.13% | - | 33,742 | - | - | 104,938 | Mar 31, 2024 |
| ALPHA SQUARE GROUP S, LLC | 0.13% | 0.19% | 33,401 | -25,545 | -43.34% | 103,877 | Mar 31, 2024 |
| XR SECURITIES LLC | 0.12% | 0.00% | 30,900 | 30,900 | 100.00% | 96,099 | Mar 31, 2024 |
| NORTHERN TRUST CORP | 0.10% | - | 25,988 | 6,567 | 33.81% | 80,823 | Mar 31, 2024 |
| HRT FINANCIAL LP | 0.09% | 0.00% | 22,587 | 22,587 | 100.00% | 70,000 | Mar 31, 2024 |
| LAFAYETTE INVESTMENTS, INC. | 0.08% | 0.01% | 19,893 | - | - | 61,868 | Mar 31, 2024 |
Rani Therapeutics's largest institutional shareholder is VANGUARD GROUP INC, holding 2.69% of the company's total share outstanding, currently valued at $2.13M. The top 10 institutional shareholders own together 10.56% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| NAN FUNG GROUP HOLDINGS LTD | 1.94% | 1.42% | 493,584 | - | - | 1,535,046 | Mar 31, 2024 |
| ALPHA SQUARE GROUP S, LLC | 0.13% | 0.19% | 33,401 | -25,545 | -43.34% | 103,877 | Mar 31, 2024 |
| LASRY MARC | 0.25% | 0.17% | 62,887 | - | - | 195,579 | Mar 31, 2024 |
| ALPHABET INC. | 1.76% | 0.06% | 448,492 | - | - | 1,394,810 | Mar 31, 2024 |
| UNITED SERVICES AUTOMOBILE ASSOCIATION | 1.89% | 0.04% | 481,300 | - | - | 1,496,843 | Mar 31, 2024 |
| ISLAY CAPITAL MANAGEMENT, LLC | 0.04% | 0.02% | 9,611 | - | - | 29,890 | Mar 31, 2024 |
| ACTIVEST WEALTH MANAGEMENT | 0.04% | 0.01% | 9,800 | - | - | 30,478,000 | Mar 31, 2024 |
| LAFAYETTE INVESTMENTS, INC. | 0.08% | 0.01% | 19,893 | - | - | 61,868 | Mar 31, 2024 |
| MOTCO | 0.19% | 0.01% | 48,129 | - | - | 149,681 | Mar 31, 2024 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.20% | 0.00% | 51,500 | - | - | 160,165 | Mar 31, 2024 |
| XR SECURITIES LLC | 0.12% | 0.00% | 30,900 | 30,900 | 100.00% | 96,099 | Mar 31, 2024 |
| CHOREO, LLC | 0.08% | 0.00% | 19,813 | - | - | 61,618 | Mar 31, 2024 |
| KING LUTHER CAPITAL MANAGEMENT CORP | 0.22% | 0.00% | 56,129 | - | - | 174,561 | Mar 31, 2024 |
| PRIME CAPITAL INVESTMENT ADVISORS, LLC | 0.05% | 0.00% | 13,882 | -2,800 | -16.78% | 43,173 | Mar 31, 2024 |
| STIFEL FINANCIAL CORP | 0.52% | 0.00% | 132,434 | 82,168 | 163.47% | 411,866 | Mar 31, 2024 |
| HRT FINANCIAL LP | 0.09% | 0.00% | 22,587 | 22,587 | 100.00% | 70,000 | Mar 31, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.28% | 0.00% | 70,300 | 26,600 | 60.87% | 219,000 | Mar 31, 2024 |
| BROWN ADVISORY INC | 0.13% | 0.00% | 33,911 | - | - | 105,463 | Mar 31, 2024 |
| TOWER RESEARCH CAPITAL LLC (TRC) | 0.00% | 0.00% | 1,239 | -1,069 | -46.32% | 3,853 | Mar 31, 2024 |
| ALLWORTH FINANCIAL LP | 0.01% | 0.00% | 3,119 | - | - | 9,701,000 | Mar 31, 2024 |
The largest Rani Therapeutics shareholder by % of total assets is NAN FUNG GROUP HOLDINGS LTD. The company owns 493.58K shares of Rani Therapeutics (RANI), representing 1.42% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| STIFEL FINANCIAL CORP | 0.52% | 0.00% | 132,434 | 82,168 | 163.47% | 411,866 | Mar 31, 2024 |
| XR SECURITIES LLC | 0.12% | 0.00% | 30,900 | 30,900 | 100.00% | 96,099 | Mar 31, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.28% | 0.00% | 70,300 | 26,600 | 60.87% | 219,000 | Mar 31, 2024 |
| HRT FINANCIAL LP | 0.09% | 0.00% | 22,587 | 22,587 | 100.00% | 70,000 | Mar 31, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.51% | - | 130,906 | 17,277 | 15.20% | 407,223 | Mar 31, 2024 |
| VANGUARD GROUP INC | 2.69% | - | 685,303 | 16,956 | 2.54% | 2,131,292 | Mar 31, 2024 |
| CITADEL ADVISORS LLC | 0.06% | - | 14,400 | 14,400 | 100.00% | 44,784 | Mar 31, 2024 |
| BANK OF AMERICA CORP /DE/ | 0.49% | - | 124,505 | 10,246 | 8.97% | 387,211,000 | Mar 31, 2024 |
| CITADEL ADVISORS LLC | 0.04% | - | 10,032 | 10,032 | 100.00% | 31,200 | Mar 31, 2024 |
| JPMORGAN CHASE & CO | 0.05% | - | 12,686 | 8,988 | 243.05% | 39,454 | Mar 31, 2024 |
| CITADEL ADVISORS LLC | 0.03% | - | 7,400 | 7,400 | 100.00% | 23,014 | Mar 31, 2024 |
| NORTHERN TRUST CORP | 0.10% | - | 25,988 | 6,567 | 33.81% | 80,823 | Mar 31, 2024 |
| UBS GROUP AG | 0.01% | - | 3,000 | 3,000 | 100.00% | 9,330 | Mar 31, 2024 |
| WELLS FARGO & COMPANY/MN | 0.00% | - | 103 | 1 | 0.98% | 320,000 | Mar 31, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | - | - | 3 | - | - | 9 | Mar 31, 2024 |
| RHUMBLINE ADVISERS | 0.00% | - | 312 | - | - | 970,000 | Mar 31, 2024 |
| BLACKROCK INC. | 0.25% | - | 63,583 | - | - | 197,743 | Mar 31, 2024 |
| STATE STREET CORP | 0.13% | - | 33,742 | - | - | 104,938 | Mar 31, 2024 |
| PNC FINANCIAL SERVICES GROUP, INC. | 0.04% | - | 9,116 | - | - | 28,351,000 | Mar 31, 2024 |
| ALLWORTH FINANCIAL LP | 0.01% | 0.00% | 3,119 | - | - | 9,701,000 | Mar 31, 2024 |
As of Mar 31 2024, Rani Therapeutics's largest institutional buyer is STIFEL FINANCIAL CORP. The company purchased 82.17K stocks of RANI, valued at $411.87K.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ALPHA SQUARE GROUP S, LLC | 0.13% | 0.19% | 33,401 | -25,545 | -43.34% | 103,877 | Mar 31, 2024 |
| SIMPLEX TRADING, LLC | 0.01% | - | 1,364 | -7,772 | -85.07% | 4,000 | Mar 31, 2024 |
| PRIME CAPITAL INVESTMENT ADVISORS, LLC | 0.05% | 0.00% | 13,882 | -2,800 | -16.78% | 43,173 | Mar 31, 2024 |
| MORGAN STANLEY | 0.01% | - | 2,451 | -2,750 | -52.87% | 7,623 | Mar 31, 2024 |
| TOWER RESEARCH CAPITAL LLC (TRC) | 0.00% | 0.00% | 1,239 | -1,069 | -46.32% | 3,853 | Mar 31, 2024 |
| IAG WEALTH PARTNERS, LLC | - | - | - | -1,005 | -100.00% | - | Mar 31, 2024 |
| NAN FUNG GROUP HOLDINGS LTD | 1.94% | 1.42% | 493,584 | - | - | 1,535,046 | Mar 31, 2024 |
| LASRY MARC | 0.25% | 0.17% | 62,887 | - | - | 195,579 | Mar 31, 2024 |
| ALPHABET INC. | 1.76% | 0.06% | 448,492 | - | - | 1,394,810 | Mar 31, 2024 |
| UNITED SERVICES AUTOMOBILE ASSOCIATION | 1.89% | 0.04% | 481,300 | - | - | 1,496,843 | Mar 31, 2024 |
| ISLAY CAPITAL MANAGEMENT, LLC | 0.04% | 0.02% | 9,611 | - | - | 29,890 | Mar 31, 2024 |
| ACTIVEST WEALTH MANAGEMENT | 0.04% | 0.01% | 9,800 | - | - | 30,478,000 | Mar 31, 2024 |
| LAFAYETTE INVESTMENTS, INC. | 0.08% | 0.01% | 19,893 | - | - | 61,868 | Mar 31, 2024 |
| MOTCO | 0.19% | 0.01% | 48,129 | - | - | 149,681 | Mar 31, 2024 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.20% | 0.00% | 51,500 | - | - | 160,165 | Mar 31, 2024 |
| CHOREO, LLC | 0.08% | 0.00% | 19,813 | - | - | 61,618 | Mar 31, 2024 |
| KING LUTHER CAPITAL MANAGEMENT CORP | 0.22% | 0.00% | 56,129 | - | - | 174,561 | Mar 31, 2024 |
| BROWN ADVISORY INC | 0.13% | 0.00% | 33,911 | - | - | 105,463 | Mar 31, 2024 |
| ALLWORTH FINANCIAL LP | 0.01% | 0.00% | 3,119 | - | - | 9,701,000 | Mar 31, 2024 |
| PNC FINANCIAL SERVICES GROUP, INC. | 0.04% | - | 9,116 | - | - | 28,351,000 | Mar 31, 2024 |
As of Mar 31 2024, Rani Therapeutics's biggest institutional seller is ALPHA SQUARE GROUP S, LLC. The company sold -25.55K shares of RANI, valued at $103.88K.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| XR SECURITIES LLC | 0.12% | 0.00% | 30,900 | 30,900 | 100.00% | 96,099 | Mar 31, 2024 |
| HRT FINANCIAL LP | 0.09% | 0.00% | 22,587 | 22,587 | 100.00% | 70,000 | Mar 31, 2024 |
| CITADEL ADVISORS LLC | 0.06% | - | 14,400 | 14,400 | 100.00% | 44,784 | Mar 31, 2024 |
| CITADEL ADVISORS LLC | 0.04% | - | 10,032 | 10,032 | 100.00% | 31,200 | Mar 31, 2024 |
| CITADEL ADVISORS LLC | 0.03% | - | 7,400 | 7,400 | 100.00% | 23,014 | Mar 31, 2024 |
Rani Therapeutics's largest new institutional shareholder by number of shares is XR SECURITIES LLC, purchased 30.90K shares, valued at $96.10K, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| IAG WEALTH PARTNERS, LLC | - | - | - | -1,005 | -100.00% | - | Mar 31, 2024 |
Rani Therapeutics's largest sold out institutional shareholder by shares sold is IAG WEALTH PARTNERS, LLC, sold -1.00K shares, valued at -, as of undefined.
Rani Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| VANGUARD VALLEY FORGE FUNDS | 0.04% | 17,809 | - | - | Dec 31, 2023 |
| BRIDGEWAY FUNDS INC | 0.02% | 51,500 | - | - | Dec 29, 2023 |
| VANGUARD INDEX FUNDS | 0.00% | 746,074 | 112,944 | 17.84% | Dec 31, 2023 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 124,026 | 16,753 | 15.62% | Feb 29, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 14,248 | - | - | Dec 31, 2023 |
| SCHWAB CAPITAL TRUST | 0.00% | 2,793 | - | - | Feb 29, 2024 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 3,944 | 3,944 | - | Jan 31, 2024 |
| GOLDMAN SACHS TRUST | 0.00% | 4,103 | - | - | Feb 29, 2024 |
| Goldman Sachs ETF Trust | 0.00% | 2,119 | - | - | Feb 29, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 280 | - | - | Dec 31, 2023 |
| PROSHARES TRUST | 0.00% | 2,060 | - | - | Feb 29, 2024 |
| iSHARES TRUST | 0.00% | 127,073 | - | - | Feb 29, 2024 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 3,926 | - | - | Feb 29, 2024 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 594 | - | - | Dec 31, 2023 |
Rani Therapeutics's largest mutual fund holder by % of total assets is "VANGUARD VALLEY FORGE FUNDS", owning 17.81K shares, compromising 0.04% of its total assets.
Rani Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 31 Mar, 24 | 37 | 15.63% |
| 31 Dec, 23 | 32 | -3.03% |
| 30 Sep, 23 | 33 | -8.33% |
| 30 Jun, 23 | 36 | - |
| 31 Mar, 23 | 36 | 5.88% |
| 31 Dec, 22 | 34 | 6.25% |
| 30 Sep, 22 | 32 | 18.52% |
| 30 Jun, 22 | 27 | 17.39% |
| 31 Mar, 22 | 23 | 9.52% |
| 31 Dec, 21 | 21 | 40.00% |
| 30 Sep, 21 | 15 | - |
As of 31 Mar 24, 37 institutions are holding Rani Therapeutics's shares, representing an increase of 15.63% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 31 Mar, 24 | 3,115,105 | 5.54% |
| 31 Dec, 23 | 2,951,624 | -8.01% |
| 30 Sep, 23 | 3,208,534 | -0.58% |
| 30 Jun, 23 | 3,227,286 | 10.20% |
| 31 Mar, 23 | 2,928,594 | -0.67% |
| 31 Dec, 22 | 2,948,381 | -7.13% |
| 30 Sep, 22 | 3,174,625 | 12.37% |
| 30 Jun, 22 | 2,825,035 | 10.49% |
| 31 Mar, 22 | 2,556,816 | 106.04% |
| 31 Dec, 21 | 1,240,939 | 13.05% |
| 30 Sep, 21 | 1,097,738 | - |
Rani Therapeutics (RANI) has 3.12M shares outstanding as of 31 Mar 24, up 5.54% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 31 Mar, 24 | 12.21% | 9.15% |
| 31 Dec, 23 | 11.55% | 7.21% |
| 30 Sep, 23 | 12.66% | 7.74% |
| 30 Jun, 23 | 12.79% | 9.50% |
| 31 Mar, 23 | 11.60% | 8.28% |
| 31 Dec, 22 | 11.84% | 7.03% |
| 30 Sep, 22 | 12.97% | 9.66% |
| 30 Jun, 22 | 11.59% | 8.13% |
| 31 Mar, 22 | 11.94% | 29.30% |
| 31 Dec, 21 | 6.38% | 20.02% |
| 30 Sep, 21 | 5.65% | - |
As of 31 Mar 24, Rani Therapeutics is held by 12.21% institutional shareholders, representing a 9.15% growth compared to 31 Dec 23.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 31 Mar, 24 | 12 | 140.00% |
| 31 Dec, 23 | 5 | -44.44% |
| 30 Sep, 23 | 9 | -43.75% |
| 30 Jun, 23 | 16 | 14.29% |
| 31 Mar, 23 | 14 | -6.67% |
| 31 Dec, 22 | 15 | -6.25% |
| 30 Sep, 22 | 16 | 23.08% |
| 30 Jun, 22 | 13 | 18.18% |
| 31 Mar, 22 | 11 | -26.67% |
| 31 Dec, 21 | 15 | - |
| 30 Sep, 21 | 15 | - |
12 institutional shareholders have increased their position in RANI stock as of 31 Mar 24 compared to 5 in the previous quarter (a 140.00% increase).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 31 Mar, 24 | 5 | -16.67% |
| 31 Dec, 23 | 6 | -14.29% |
| 30 Sep, 23 | 7 | 250.00% |
| 30 Jun, 23 | 2 | -50.00% |
| 31 Mar, 23 | 4 | -50.00% |
| 31 Dec, 22 | 8 | - |
| 30 Sep, 22 | 8 | 33.33% |
| 30 Jun, 22 | 6 | -14.29% |
| 31 Mar, 22 | 7 | 250.00% |
| 31 Dec, 21 | 2 | - |
| 30 Sep, 21 | - | - |
5 institutional shareholders have reduced their position in RANI stock as of 31 Mar 24 compared to 6 in the previous quarter (a -16.67% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 31 Mar, 24 | 37 | 15.63% | 3,115,105 | 5.54% | 12.21% | 9.15% | 12 | 140.00% | 5 | -16.67% |
| 31 Dec, 23 | 32 | -3.03% | 2,951,624 | -8.01% | 11.55% | 7.21% | 5 | -44.44% | 6 | -14.29% |
| 30 Sep, 23 | 33 | -8.33% | 3,208,534 | -0.58% | 12.66% | 7.74% | 9 | -43.75% | 7 | 250.00% |
| 30 Jun, 23 | 36 | - | 3,227,286 | 10.20% | 12.79% | 9.50% | 16 | 14.29% | 2 | -50.00% |
| 31 Mar, 23 | 36 | 5.88% | 2,928,594 | -0.67% | 11.60% | 8.28% | 14 | -6.67% | 4 | -50.00% |
| 31 Dec, 22 | 34 | 6.25% | 2,948,381 | -7.13% | 11.84% | 7.03% | 15 | -6.25% | 8 | - |
| 30 Sep, 22 | 32 | 18.52% | 3,174,625 | 12.37% | 12.97% | 9.66% | 16 | 23.08% | 8 | 33.33% |
| 30 Jun, 22 | 27 | 17.39% | 2,825,035 | 10.49% | 11.59% | 8.13% | 13 | 18.18% | 6 | -14.29% |
| 31 Mar, 22 | 23 | 9.52% | 2,556,816 | 106.04% | 11.94% | 29.30% | 11 | -26.67% | 7 | 250.00% |
| 31 Dec, 21 | 21 | 40.00% | 1,240,939 | 13.05% | 6.38% | 20.02% | 15 | - | 2 | - |
| 30 Sep, 21 | 15 | - | 1,097,738 | - | 5.65% | - | 15 | - | - | - |
Rani Therapeutics Insider Shareholders Trades
Open Market Insider Trades
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Open Market Insider Buys
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Insider Sells
All Insider Owners Trades
The last insider sell of Rani Therapeutics's stock was made by Sanford Svai S on Dec 19 2023, selling 83,724 shares at $9.44 per share (valued at $790.35K).
Rani Therapeutics Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q1 2024 | 5 | - | - |
| Q4 2023 | 34 | 27 | 125.93% |
| Q3 2023 | - | - | - |
| Q2 2023 | 27 | - | - |
| Q1 2023 | 29 | 4 | 725.00% |
| Q4 2022 | 31 | - | - |
| Q3 2022 | 2 | 4 | 50.00% |
| Q2 2022 | 10 | - | - |
| Q1 2022 | 13 | 7 | 185.71% |
| Q4 2021 | 1 | 1 | 100.00% |
| Q3 2021 | 6 | 36 | 16.67% |
5 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Rani Therapeutics's insiders, as of Q1 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q1 2024 | - | - | - |
| Q4 2023 | 8 | 1 | 800.00% |
| Q3 2023 | - | - | - |
| Q2 2023 | 19 | - | - |
| Q1 2023 | 21 | - | - |
| Q4 2022 | 31 | - | - |
| Q3 2022 | - | 2 | - |
| Q2 2022 | - | - | - |
| Q1 2022 | - | - | - |
| Q4 2021 | - | - | - |
| Q3 2021 | 3 | - | - |
As of Q1 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Rani Therapeutics's stocks.
Rani Therapeutics Peer Ownership
| Ticker | Company |
|---|---|
| SRZN | Surrozen, Inc. |
| PMVP | PMV Pharmaceuticals, Inc. |
| TYRA | Tyra Biosciences, Inc. |
| BMEA | Biomea Fusion, Inc. |
| CRVS | Corvus Pharmaceuticals, Inc. |
| EYPT | EyePoint Pharmaceuticals, Inc. |
| VINC | Vincerx Pharma, Inc. |
| SQZ | SQZ Biotechnologies Company |
| TNYA | Tenaya Therapeutics, Inc. |
| VIRX | Viracta Therapeutics, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| ALXO | ALX Oncology Holdings Inc. |
| TCON | TRACON Pharmaceuticals, Inc. |
| MNPR | Monopar Therapeutics Inc. |
| PHVS | Pharvaris N.V. |
| CABA | Cabaletta Bio, Inc. |
| TARA | Protara Therapeutics, Inc. |
| TRVI | Trevi Therapeutics, Inc. |
| MOLN | Molecular Partners AG |
| LYRA | Lyra Therapeutics, Inc. |
| VCNX | Vaccinex, Inc. |
RANI Ownership FAQ
Who Owns Rani Therapeutics?
Rani Therapeutics is owned by institutional shareholders (12.21%), insiders (48.88%), and public (38.91%). The largest institutional shareholder of Rani Therapeutics is VANGUARD GROUP INC (2.69% of total shares) and the top mutual fund owner is VANGUARD VALLEY FORGE FUNDS (0.04% of total shares).
Who are the major institutional shareholders of Rani Therapeutics?
Rani Therapeutics's major institutional shareholders are VANGUARD GROUP INC, NAN FUNG GROUP HOLDINGS LTD, UNITED SERVICES AUTOMOBILE ASSOCIATION, ALPHABET INC., and STIFEL FINANCIAL CORP. The top five shareholders own together 8.79% of the company's share outstanding.
How many Rani Therapeutics shareholders are there?
As of Mar 2024, there are 37 institutional shareholders of Rani Therapeutics.
What percentage of Rani Therapeutics is owned by VANGUARD GROUP INC?
VANGUARD GROUP INC owns 685.3K shares of Rani Therapeutics, representing 2.69% of the company's total shares outstanding, valued at $2.13M (as of Mar 2024).
What percentage of Rani Therapeutics is owned by NAN FUNG GROUP HOLDINGS LTD?
As of Mar 2024, NAN FUNG GROUP HOLDINGS LTD holds 493.58K shares of Rani Therapeutics (RANI), compromising 1.94% of the company, valued at $1.54M.
What percentage of Rani Therapeutics is owned by UNITED SERVICES AUTOMOBILE ASSOCIATION?
UNITED SERVICES AUTOMOBILE ASSOCIATION is the third largest holder of Rani Therapeutics. The company owns 481.3K of the company's shares outstanding (worth $1.5M).